Eric Venker Sells 200,000 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 200,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $33.16, for a total transaction of $6,632,000.00. Following the transaction, the chief executive officer owned 1,613,063 shares of the company’s stock, valued at approximately $53,489,169.08. This represents a 11.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eric Venker also recently made the following trade(s):

• On Friday, May 22nd, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $30.27, for a total transaction of $6,054,000.00.
• On Monday, April 20th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $29.59, for a total transaction of $5,918,000.00.

Roivant Sciences Trading Up 0.1%

Shares of Roivant Sciences stock opened at $34.07 on Friday. The company has a market capitalization of $24.51 billion, a PE ratio of -56.78 and a beta of 1.13. Roivant Sciences Ltd. has a 12 month low of $10.70 and a 12 month high of $34.68. The stock’s fifty day simple moving average is $29.66 and its 200 day simple moving average is $26.77.

Roivant Sciences (NASDAQ:ROIV) last posted its earnings results on Wednesday, May 20th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.57. The firm had revenue of $2.52 million during the quarter, compared to analysts’ expectations of $3.41 million. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.During the same period in the previous year, the firm earned ($0.29) earnings per share. Analysts predict that Roivant Sciences Ltd. will post -1.83 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ROIV. Piper Sandler reissued an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st. Weiss Ratings lowered Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Guggenheim increased their price objective on Roivant Sciences from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, May 26th. Jefferies Financial Group reissued a “buy” rating on shares of Roivant Sciences in a research report on Tuesday, March 3rd. Finally, Leerink Partners set a $42.00 price target on shares of Roivant Sciences in a research note on Thursday, May 21st. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $33.59.

Institutional Trading of Roivant Sciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. grew its position in shares of Roivant Sciences by 1,740.3% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after acquiring an additional 1,166 shares during the period. Allworth Financial LP raised its holdings in shares of Roivant Sciences by 48.1% in the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after purchasing an additional 583 shares during the period. Parallel Advisors LLC lifted its stake in Roivant Sciences by 33.7% in the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock valued at $57,000 after purchasing an additional 520 shares during the last quarter. Kestra Advisory Services LLC bought a new position in Roivant Sciences during the fourth quarter worth about $47,000. Finally, Bessemer Group Inc. increased its position in Roivant Sciences by 21.8% during the first quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock worth $69,000 after buying an additional 441 shares during the last quarter. 64.76% of the stock is owned by institutional investors.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.